Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma

• Published in: Modern pathology 2022-11, Vol.35 (11), p.1618-1623
• Main Authors: Margolis, Matthew, Janovitz, Tyler, Laird, Jason, Mata, Douglas A., Montesion, Meagan, Lee, Jessica K., Madison, Russell W., Schrock, Alexa B., Tukachinsky, Hanna, Allen, Justin M., Erlich, Rachel, Hiemenz, Matthew C., Huang, Richard S.P., Elvin, Julia, Vergilio, Jo-Anne, Lin, Douglas I., Ross, Jeffrey, Oxnard, Geoffrey, Decker, Brennan
• Format: Article
• Language: English
• Subjects: 14/63; 45/23; 631/67/1536/1665; 631/67/395; 631/67/69; Adenoid; Antibodies, Monoclonal; Cancer; Carcinoma; Carcinoma, Adenoid Cystic - genetics; Carcinoma, Adenoid Cystic - pathology; Codons; Fibronectin; Fibronectins; Humans; Kinases; Laboratory Medicine; Medicine; Medicine & Public Health; Monoclonal antibodies; Oral cancer; Pathology; Protein Kinase Inhibitors; Protein-tyrosine kinase receptors; Receptor, IGF Type 1 - genetics; Salivary gland; Salivary Gland Neoplasms - genetics; Salivary Gland Neoplasms - pathology; Tumors
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/s41379-022-01126-3

Activation of the tyrosine kinase receptor IGF1R is targetable with existing tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, but mutations in IGF1R have not been systematically characterized. Pan-cancer analysis of 326,911 tumors identified two distinct, activating non-frameshift insertion hotspots in IGF1R, which were significantly enriched in adenoid cystic carcinomas (ACCs). IGF1R alterations from 326,911 subjects were analyzed by variant effect prediction class, position within the gene, and cancer type. 6502 (2.0%) samples harbored one or more alterations in IGF1R. Two regions were enriched for non-frameshift insertions: codons 663–666 at the hinge region of the fibronectin type 3 domain and codons 1034–1049 in the tyrosine kinase domain. Hotspot insertions were highly enriched in ACCs (27.3-fold higher than in the remainder of the pan-cancer dataset; P = 2.3 × 10−17). Among salivary gland tumors, IGF1R hotspot insertions were entirely specific to ACCs. IGF1R alterations were most often mutually exclusive with other ACC drivers (9/15, 60%). Tumors with non-frameshift hotspot IGF1R insertions represent a novel, potentially targetable subtype of ACC. Additional studies are needed to determine whether these patients respond to existing IGF1R inhibitors.